This OncLive panel discussion focuses on the treatment of renal cell carcinoma (RCC) with vaccines, specifically the results from the ADAPT trial, and suggest that the way forward for vaccine treatment is in combination with other RCC drugs. They then move on to talk about combination trials with immunotherapy and TKI drugs; however, combinations of drugs are not always well tolerated.

See the video here